Skip to main content

Table 2 Major clinical end points (intention-to-treat population)

From: Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial

Endpoint

Colchicine

Placebo

Hazard ratio (95%CI)

P value

Total MACE

8 (6.7)

28 (21.7)

3.52 (1.60–7.74)

0.001

ACS

4 (3.3)

25 (19.4)

1.82 (1.49 – 2.23)

 < 0.001

STEMI

0

3 (2.3)

1.95 (1.72 – 2.20)

0.093

NSTEMI

2 (1.7)

8 (6.2)

1.58 (1.13 – 2.20)

0.069

UA

2 (1.7)

14 (10.9)

1.77 (1.41 – 2.22)

0.003

DHF

0

1 (0.8)

1.93 (1.71 – 2.18)

0.334

Death

    

any cause

4 (3.3)

2 (1.6)

0.63 (0.20 – 1.99)

0.359

cardiovascular

4 (3.3)

2 (1.6)

0.63 (0.20 – 1.99)

0.359

  1. Cox regression model clustered over multiple events with an individual and adjusted for group
  2. assignment.ACS, acute coronary syndrome; NSTEMI, non-ST segment elevation acute coronary syndrome; UA, unstable angina; DHF, decompensated heart failure
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us